DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
XP19986 is an investigational drug.
There have been 6 clinical trials for XP19986. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2011.
The most common disease conditions in clinical trials are Gastroesophageal Reflux, Spinal Cord Injuries, and Muscle Spasticity. The leading clinical trial sponsors are Indivior Inc. and [disabled in preview].
There are nineteen US patents protecting this investigational drug and eighty-two international patents.
Recent Clinical Trials for XP19986
|Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis||Indivior Inc.||Phase 3|
|A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)||Indivior Inc.||Phase 2|
|A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms||Indivior Inc.||Phase 2|
Top disease conditions for XP19986
Top clinical trial sponsors for XP19986
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|XP19986||Start Trial||Sustained release oral dosage forms of an R-baclofen prodrug||XENOPORT, INC. (Santa Clara, CA)||Start Trial|
|XP19986||Start Trial||Acyloxyalkyl carbamate prodrugs, methods of synthesis and use||XenoPort, Inc. (Santa Clara, CA)||Start Trial|
|XP19986||Start Trial||Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof||XenoPort, Inc. (Santa Clara, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|